Despite the development of new anti-ischemic drugs and the improvements in revascularisation techniques, a substantial proportion of patients with ischemic heart disease remain symptomatic with severe debilitating angina. The major aim of therapy for these patients should be aggressive modification of risk factors and optimising medical and interventional treatment. Nevertheless, when disease progresses and standard treatments are not possible, new strategies should be established. In this setting, treatment with peripheral blood-derived stem cells using the transendocardial injection is a new promising option.
INTRODUCTION
Refractory angina constitutes a serious clinical problem. The European Society of Cardiology has defined refractory angina as a chronic condition (> 3 months) characterised by the presence of angina caused by coronary insufficiency due to coronary artery disease which can not be controlled by a combination of medical therapy, angioplasty and coronary bypass surgery. 1 The prevalence of refractory angina is growing due to the improvement in the survival of patients with coronary heart disease. Patients with no options may account for up to 12% of those referred for diagnostic catheterisation. Reason for ineligibility include: the presence of diffuse coronary disease, disease in small distal vessels, recurrent in stent restenosis, chronic total occlusion and multivessel disease in patients with important co-morbidities. 2 Although mortality rate in this kind of patients is low the effect in the quality of life is very high 3,4. Patients with chronic angina present increasing levels of anxiety, depression and psychological stress that may worsen the degree of disability. Furthermore, it has been proved in large-scale clinical trials that the quality of life has prognostic value. The IONA study group found that basal severity of angina (Canadian Cardiovascular Society [CCS] grading) was a powerful independent risk factor of cardiovascular death or non fatal myocardial infarction. 5
There is no doubt that strategies aimed at reducing coronary disease progression, coronary events and angina rate (Table 1) are essential reducing both cardiovascular morbidity and mortality; however, other multidisciplinary treatments should be incorporated such as cardiac rehabilitation and psychological support. 6, 7, 8 There are additional treatment possibilities for patients with refractory angina that are not considered as a standard therapy. These other options of treatment include enhanced external counterpulsation 9 , spinal cord stimulation 10 or transmyocardial laser revascularisation 11,12,13 . There are several randomised clinical trials and registries assessing the efficacy of these therapies as compared to placebo in patients with refractory angina. Although most of them have shown significant clinical improvement, inconsistent results about the effect on exercise capacity or myocardial perfusion are reported. The regenerative medicine with stem cells has emerged as a promising field, especially in the clinical setting of refractory angina. In this regard, several studies have been published and others are ongoing. In this review we will focus on bone marrow derived stem cell 14 transplantation as a novel option for the treatment of patients with refractory angina. These authors demonstrated reendothelisation of a dacron graft with cells that came from the transplanted bone marrow, confirming the bone marrow origin of endothelial progenitor cells. Moreover, Quaini et al. 18 supported the theory of an extrinsic vascular repair system by using a chimerism model (female heart transplanted into a male host). In this study Y chromosome + cells were found as a part of vascular structures in the heart showing the ability of extracardiac progenitor cells to engraft and develop vessels.
Treatment

Level of evidence
A change in the paradigm
Transendocardical injection guided by electroanatomical mapping systems.
There are several methods to deliver stem cells to the heart. In patients with refractory angina the preferred delivery method is direct transendocardial injection guided by electromechanical mapping. This method allows us to guide the stem cell delivery in a safe and fast fashion. 19, 20 The maps are constructed by combining and integrating information from intracardiac electrograms with the respective endocardial locations. The NOGA® XP System (BiosenseWebster, Diamond Bar, California) develops a low power magnetic field where catheters equipped with a location sensor provides real-time information on the location of the catheter.
The NOGA® XP System enables analysis of both global and local parameters that characterise mechanical, dynamic and electrical function of the mapped cardiac chamber. Among the global parameters provided in NOGA® XP maps are end-diastolic volume (EDV), endsystolic volume (ESV), stroke volume (SV) and ejection fraction (EF). Local functional analysis is based on local shortening data as tests of local mechanical function, and measurements of local intracardiac signals as tests of electrical functionality. Combined, these data provide information about the local electromechanical coupling. showed that transendocardial injection of bone marrow mononuclear cells into the ischemic myocardium of pigs significantly increased myocardial perfusion as well as local contractility in the treatment group as compared with the control. 27 No safety issues were derived from these two studies.
Clinical trials in no-option patients
Based on these preclinical observations, preliminary clinical studies have been performed in no option patients. The majority of them are non randomised, uncontrolled studies and have used the mononuclear fraction of the bone marrow. The delivery method, in all but one of them, was the NOGA guided transendocardial injection platform. These studies have shown the safety and the feasibility of the procedure and very promising results in terms of efficacy (Table 2) .
Four randomised trials have been performed in no option patients. The FOCUS trial has been conducted by the group at the Texas Heart Institute, Houston. This study has not been published yet; however, Dr. E. Perin presented the preliminary results in the Fourth International Conference on Cell Therapy for Cardiovascular Diseases. In this trial, 30 patients were included in a 2:1 randomised fashion to receive 30 million bone marrow mononuclear cells or placebo. At three months follow-up a significant reduction in angina functional class and an increase in perfusion measured by SPECT were observed in the treatment group; whereas no significant changes were reported in the control group. In this study, the total exercise time and the left ventricular ejection fraction significantly improved in the cell group whereas no differences were observed in the control group. The most recent study was conducted in the Netherlands 30 , in which 50 patients with chronic myocardial ischemia were included. The patients were randomly assigned to receive intramyocardial injection of autologous bone marrow-derived mononuclear cells or placebo solution. After 3-month follow up, single photon emission computed tomography-summed stress score-improved from 23,5 to 20,1 (p<0,001) in the bone marrow cell group, compared with a decrease from 24,8 to 23,7 (p=0,004) in the placebo group.
A 3% absolute increase in left ventricular ejection fraction, measure by magnetic resonance imaging, was observed only in the bone marrow cell group. CCS angina score improved significantly in the bone marrow cell group compared with no significant improvement in the placebo group. Quality-of-life score (measure by Seattle Angina Questionnaire) increased from 56% to 64% compared with a smaller increase in the placebo group 57% to 61%. The improvements in CCS class and quality of life score were significantly greater in bone marrow cell-treated patients than in placebo-treated patients (p = .03 and p = .04, respectively).
There are several trials ongoing. The FOCUS trial 31 is an ongoing randomised study that will assess the effect of autologous bone marrow mononuclear cells delivered transendocardially to patients with left ventricular (LV) dysfunction and symptomatic heart failure or angina. They plan to recruit 87 patients (58 treated and 29 controls) and will have myocardial perfusion, LV contractile performance and maximal oxygen consumption as primary outcomes. Patients will be followed for at least five years. The Baxter ACT 34 CMI is a phase II randomised trial that will included 150 patients with refractory angina. The patients will be treated by trasnendocardial injection of an enriched fraction of CD34+ cells or placebo. Finally, the PROGENITOR trial is a multicentre, randomised and double-blind study conducted by our group in Spain.
There is no official sponsor of this trial and is has been supported by a Spanish Health Ministry Grant and a Mutua Madrileña Foundation Grant. The PROGENITOR trial is still in recruitment phase. The main inclusion criteria are patients with demonstrated myocardial ischemia in a certain territory without any option of revascularisation (percutaneous or surgical) and symptomatic for angina despite optimal medical treatment (refractory angina) and will be randomised to received transendocardial injection of an enriched fraction of CD133+ cells isolated from the peripheral blood cells or placebo. CD 133+ is a surface antigen with unknown functional relevance and is an early haematopoyetic stem cell marker, that is not expressed in mature endothelial cells and therefore, CD 133+ defines a primitive population of cells with the capacity to differentiate into endothelial cells. Furthermore, there is a subpopulation of these cells that are CD 34 -which are functionally more potent than CD34+ CD133+ positive cells.
To the best of our knowledge, this is the first-in-man trial with transendocardial injection of peripheral selected CD133+ cells in nooption patients. 
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